Icon Writers / 09 12 月, 2020


In late 2019 Icon Group became the first Australian healthcare company to deliver cancer care into Mainland China. One year later the group continues to provide more care to where it is needed with the opening of two more centres located in China’s Chongqing and Qingdao.

On 28th November 2020, the new Icon Cancer Centre located inside Qingdao United Family Healthcare (UFH) Hospital was officially opened alongside the 20th Radiotherapy Annual Conference of Qingdao. The new state-of-the-art centre is equipped with a Varian, TrueBeam linear accelerator, the latest in radiation therapy technology. This machine is the first of its kind in Qingdao and delivers pin-point accurate treatments and radiation therapy techniques for a wide range of cancer types.

Leveraging Icon’s international clinical expertise, the centre will also offer Varian’s HyperArc technology – an advanced radiation therapy technology delivering stereotactic radiosurgery which intelligently adapts to the size, shape and location of tumours. It is used to accurately treat multiple brain metastases and is designed to improve quality of life for patients living with advanced secondary cancers.

青島和睦家醫院內 ICON癌症中心的開業見證了集團為貫徹「竭盡所能將優質醫療護理服務擴展至更多地方,為更多有需要人士提供服務」願景,努力與更多方建立更緊密合作關係的付出。

Mark Middleton表示:「和睦家醫院是一間備受國際認可的醫療集團,在中國醫療保健市場屹立超過20年。憑藉其對中國醫療保健體系的廣泛了解,加上ICON 提供世界先進放射治療服務的經驗,我們相信能為身處中國內地的人士提供更高水平的癌症醫療和護理服務。」




In the past year, Icon’s first cancer centre in Jiangxian has been treating cancer patients across the Shanxi province eliminating the need to travel long distances into metropolitan cities for the same level of world-class care. Icon is now bringing this standard of care to the people of Chongqing and Qingdao.

“We chose to build a centre in Qingdao because it was an area in need. Delivering care where it is needed most is in Icon’s DNA, we’ve brought care to regional Australia for decades and now we are exporting that same level of care into China, because we believe no one should feel helpless in their time of need. Our growth in Asia delivers on this belief as we continue to forge a path forward for better access to the absolute latest in cancer care.”

查看所有 新聞